ClinicalTrials.gg
RecruitingNCT07577674STEPP-CareUpdated Nov 18, 2026

Peer Support Intervention for Caregivers of Patients Undergoing HSCT

An interventional study of STEPP-Care in Hematopoietic Stem Cell Transplantation, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to determine if a tailored peer support intervention (STEPP-Care) is feasible among caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT).

Read the detailed description

Caregivers play a vital role in recovery following hematopoietic stem cell transplantation (HSCT). However, caregiving can contribute to psychological distress and reduced quality of life (QOL). Additionally, HSCT caregivers report low self-efficacy and social support, protective factors which would otherwise help bolster their confidence in coping with the uncertainties and challenges of HSCT. Given the challenges and unmet psychosocial needs of HSCT caregivers, peer support interventions are poised to promote caregiver coping to address caregiver distress and quality of life concerns. With limited tailored peer support interventions, for HSCT caregivers, this study aims to assess the feasibility and acceptability of a peer support intervention (STEPP-Care) and examine its preliminary effects for improving QOL, caregiver burden, and psychological well-being compared to usual care in 90 caregivers of HSCT recipients.

02

Conditions studied

  • Hematopoietic Stem Cell Transplantation

Keywords

  • Caregivers
  • Stem Cell Transplantation
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult caregivers (≥18 years of age) of patients with hematologic who are undergoing or allogeneic HSCT at Dana-Farber Cancer Institute.
  • Is a relative or friend who is identified by the patient to be their caregiver.
  • Ability to speak, read, and respond in English
  • Has access to a phone.

Exclusion criteria

Exclusion Criteria:

  • Caregivers with acute or unstable psychiatric conditions or other cognitive conditions that the treating oncologist believes would prohibit or ability to adhere to study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    STEPP-Care

    STEPP-Care is a phone delivered six session structured peer support intervention.

    Behavioral: STEPP-Care

  • No intervention
    Usual Care

    Routine supportive care provided by social workers embedded in the HCT clinical teams will be used as the usual care control condition.

Interventions

  • BehavioralSTEPP-Care

    STEPP-Care is a phone-delivered six-session structured peer support intervention for caregivers of patients undergoing hematopoietic stem cell transplantation.

06

What researchers measure

Primary outcomes

  1. Intervention Feasibility

    Feasibility can be defined as \>/= 60% of STEPP-Care recipients completing 4/6 sessions

    Time frame: up to 10 weeks

  2. Intervention Acceptability

    Acceptability can be defined as average STEPP-Care intervention participant ratings \>20 on the Client Satisfaction Questionnaire

    Time frame: up to 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 23 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 11, 2026
StartActual
Oct 19, 2026was Sep 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in United States
Show site
  • Dana Farber Cancer Institute · Boston, United States
Nov 18, 2026
Start date
Sep 30, 2026→Oct 19, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Dana Farber Cancer Institute · Boston, United States
    Start date Sep 30, 2026→Oct 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577674
Responsible party
Hermioni L.Amonoo, MD, MPP, MPH (Director, Well-Being and Cancer Research Program, Brigham and Women's Hospital) — Principal investigator
First posted
May 11, 2026
Start date
Oct 19, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Hermioni L. Amonoo, MD, MPP, MPH
Contact
hermioni_amonoo@dfci.harvard.edu
617-525-7472
Josephine Monahan, BA
Contact
jamonahan@bwh.harvard.edu
Hermioni L. Amonoo, MD, MPP, MPH
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion